Improving engineered T cell therapy for pancreatic cancer
Official title: Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma
Funded at University of Minnesota · NIH-11143879 · Data updated 2026-11-12
A new engineered T cell approach aims to attack pancreatic cancer and its protective tumor environment to help people with advanced pancreatic cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | September 16, 2021 |
| Project end | July 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $354,563 |
| NIH project number | 5R01CA255039-05 |
| Project ID | NIH-11143879 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with advanced or metastatic pancreatic ductal adenocarcinoma whose tumors express mesothelin and who are eligible for experimental cellular therapies would be the most relevant candidates.
✕Less likely to help
Patients whose tumors lack mesothelin expression or who are medically unfit for adoptive cell therapy may not benefit from this approach.
What this research studies
This project engineers T cells to recognize mesothelin, a protein commonly found on pancreatic tumor cells, and tests how well those T cells penetrate and act within tumors. Experiments are done in animal models that mimic human pancreatic ductal adenocarcinoma to observe tumor shrinkage, changes in the surrounding stromal tissue, and effects on immune-suppressive cells. Researchers measure which T cell properties lead to stronger anti-tumor responses and longer survival in these models. Results are intended to guide development of safer and more effective T cell therapies that could move toward human testing.
Why it matters
Potential benefit: If successful, this approach could lead to more effective T cell immunotherapies that shrink pancreatic tumors and extend survival.
How similar studies have gone: Engineered T cell therapies have shown strong benefits in some blood cancers and early preclinical or early-phase work targeting mesothelin has been promising, but pancreatic tumors remain particularly challenging.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Stromnes, Ingunn Margarete — University of Minnesota
- Study coordinator: Stromnes, Ingunn Margarete
Related research
Other NIH-funded projects on the same topics.
-
Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer
This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.
-
TREM2+ macrophages and liver metastases in pancreatic cancer
Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.
-
Protein S could slow pancreatic cancer and blood clots
A potential treatment study looks at restoring a natural blood protein, Protein S, to help people with pancreatic cancer by slowing tumor growth and reducing dangerous clots.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
-
Metabolic changes in pancreatic cancer when treated with crisantaspase
Aims to understand how pancreatic cancer cells adapt their metabolism when treated with crisantaspase to inform better treatment strategies for patients.
-
New combination therapy for pancreatic cancer in animals
A new therapy designed to weaken the tumor’s protective surroundings and boost treatment effects in pancreatic cancer models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.